A global, innovation-driven, biopharmaceutical company

Our view

  • AstraZeneca’s sales and profits have declined over the last years due to a number of key products going off patents.
  • To achieve future growth, it is important that AstraZeneca brings new and innovative treatments to the market.
  • Encouraging pipeline progress has been made in recent years, although readouts in 2017 were mixed. The coming years will be important in terms of late-stage pipeline readouts and commercialization of approved products.
Visit the company website

Company facts

Registered Office:

London, UK


London, New York, Stockholm

Business Area:

Listed Core Investments

Share of total assets (%):


Ownership capital/votes (%):


Investment Year:


Serving On The Board:

Marcus Wallenberg
investor pattern